Table 2. Replication and Meta-Analysis of the Association Between Genetically Predicted Triglycerides and Risk of Venous Thromboembolism in the INVENT Consortium (Odds Ratios with 95% Confidence Intervals).

Venous Thromboembolism	N Events/Participants	HDL-Cholesterol	LDL-Cholesterol	Triglycerides
UK Biobank	14 097 / 367 703	0.94 (0.82–1.08)	1.03 (0.92–1.16)	0.79 (0.67–0.93)*
INVENT	15 572 / 129 002	1.03 (0.89–1.20)	1.07 (0.94–1.21)	0.84 (0.70–1.01)
UK Biobank+INVENT	29 669 / 496 705	0.98 (0.86–1.12)	1.05 (0.94–1.17)	0.81 (0.69–0.95)*

All estimates are odds ratios estimated using multivariable inverse-variance weighted Mendelian randomization accounting for lipid-related genetic pleiotropy and between-variant heterogeneity (random-effects analyses). HDL indicates high-density lipoprotein; and LDL, low-density lipoprotein.

^*P<0.05